Jade Biosciences, Inc. (JBIO) Scorecard
- 2026-Q2: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Win.
21/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
WinJBIO / S&P 58.15% / 15.20% |
LoseJBIO / S&P JBIO unavailable / 15.00% |
LoseJBIO / S&P -89.62% / 50.40% |
| 2026-Q10/3 |
LoseJBIO / S&P -8.94% / -4.33% |
LoseJBIO / S&P JBIO unavailable / 11.30% |
LoseJBIO / S&P -89.08% / 27.70% |
| 2025-Q42/3 |
WinJBIO / S&P 78.79% / 2.65% |
LoseJBIO / S&P JBIO unavailable / 9.00% |
WinJBIO / S&P 87.41% / 13.40% |
| 2025-Q31/3 |
LoseJBIO / S&P -13.61% / 8.12% |
LoseJBIO / S&P JBIO unavailable / 4.61% |
WinJBIO / S&P 75.19% / 13.45% |
| 2025-Q21/3 |
LoseJBIO / S&P -88.33% / 10.94% |
LoseJBIO / S&P JBIO unavailable / 4.83% |
WinJBIO / S&P 489.17% / 10.63% |
| 2025-Q11/3 |
LoseJBIO / S&P -5.28% / -4.27% |
LoseJBIO / S&P JBIO unavailable / 4.98% |
WinJBIO / S&P 508.55% / 10.57% |
| 2024-Q42/3 |
WinJBIO / S&P 26.79% / 2.41% |
LoseJBIO / S&P JBIO unavailable / 5.25% |
WinJBIO / S&P 151.04% / 6.15% |
| 2024-Q32/3 |
WinJBIO / S&P 25.90% / 5.89% |
LoseJBIO / S&P JBIO unavailable / 5.89% |
WinJBIO / S&P 182.91% / 6.11% |
| 2024-Q21/3 |
LoseJBIO / S&P -94.39% / 4.28% |
LoseJBIO / S&P JBIO unavailable / 5.38% |
WinJBIO / S&P 20.77% / 5.12% |
| 2024-Q12/3 |
WinJBIO / S&P 30.67% / 10.56% |
LoseJBIO / S&P JBIO unavailable / 5.71% |
WinJBIO / S&P 30.47% / 5.59% |
| 2023-Q42/3 |
WinJBIO / S&P 66.76% / 11.69% |
LoseJBIO / S&P JBIO unavailable / 6.81% |
WinJBIO / S&P 36.49% / 7.78% |
| 2023-Q31/3 |
LoseJBIO / S&P -20.87% / -3.27% |
LoseJBIO / S&P JBIO unavailable / 7.52% |
WinJBIO / S&P 75.16% / -5.03% |
| 2023-Q21/3 |
LoseJBIO / S&P -14.97% / 8.74% |
LoseJBIO / S&P JBIO unavailable / 9.50% |
WinJBIO / S&P 104.72% / -8.57% |
| 2023-Q10/3 |
LoseJBIO / S&P -31.16% / 7.50% |
LoseJBIO / S&P JBIO unavailable / 10.77% |
LoseJBIO / S&P JBIO unavailable / -15.69% |
| 2022-Q41/3 |
WinJBIO / S&P 76.72% / 7.56% |
LoseJBIO / S&P JBIO unavailable / 11.88% |
LoseJBIO / S&P JBIO unavailable / -17.99% |
| 2022-Q31/3 |
WinJBIO / S&P 6.08% / -4.88% |
LoseJBIO / S&P JBIO unavailable / 13.47% |
LoseJBIO / S&P JBIO unavailable / -1.41% |
| 2022-Q21/3 |
WinJBIO / S&P -14.73% / -16.10% |
LoseJBIO / S&P JBIO unavailable / 13.71% |
LoseJBIO / S&P JBIO unavailable / 11.04% |
| 2022-Q11/3 |
WinJBIO / S&P 55.47% / -4.60% |
LoseJBIO / S&P JBIO unavailable / 15.97% |
LoseJBIO / S&P JBIO unavailable / 42.23% |
| 2021-Q40/3 |
LoseJBIO / S&P -43.80% / 11.03% |
LoseJBIO / S&P JBIO unavailable / 15.00% |
LoseJBIO / S&P JBIO unavailable / 96.40% |
| 2021-Q30/3 |
LoseJBIO / S&P -8.10% / 0.58% |
LoseJBIO / S&P JBIO unavailable / 10.77% |
LoseJBIO / S&P JBIO unavailable / 69.42% |
| 2021-Q20/3 |
LoseJBIO / S&P JBIO unavailable / 8.55% |
LoseJBIO / S&P JBIO unavailable / 6.58% |
LoseJBIO / S&P JBIO unavailable / 51.81% |
| 2021-Q10/3 |
LoseJBIO / S&P JBIO unavailable / 6.17% |
LoseJBIO / S&P JBIO unavailable / -1.06% |
LoseJBIO / S&P JBIO unavailable / 7.39% |
| 2020-Q40/3 |
LoseJBIO / S&P JBIO unavailable / 12.15% |
LoseJBIO / S&P JBIO unavailable / -3.72% |
LoseJBIO / S&P JBIO unavailable / -33.42% |
| 2020-Q30/3 |
LoseJBIO / S&P JBIO unavailable / 8.93% |
LoseJBIO / S&P JBIO unavailable / -2.04% |
LoseJBIO / S&P JBIO unavailable / -27.10% |
| 2020-Q20/3 |
LoseJBIO / S&P JBIO unavailable / 20.54% |
LoseJBIO / S&P JBIO unavailable / -0.46% |
LoseJBIO / S&P JBIO unavailable / -27.11% |
| 2020-Q10/3 |
LoseJBIO / S&P JBIO unavailable / -19.60% |
LoseJBIO / S&P JBIO unavailable / 3.47% |
LoseJBIO / S&P JBIO unavailable / -14.75% |
| 2019-Q40/3 |
LoseJBIO / S&P JBIO unavailable / 9.07% |
LoseJBIO / S&P JBIO unavailable / 5.36% |
LoseJBIO / S&P JBIO unavailable / 2.99% |
| 2019-Q30/3 |
LoseJBIO / S&P JBIO unavailable / 1.70% |
LoseJBIO / S&P JBIO unavailable / 5.02% |
LoseJBIO / S&P JBIO unavailable / 0.21% |
| 2019-Q20/3 |
LoseJBIO / S&P JBIO unavailable / 4.30% |
LoseJBIO / S&P JBIO unavailable / 6.64% |
LoseJBIO / S&P JBIO unavailable / 8.65% |
| 2019-Q10/3 |
LoseJBIO / S&P JBIO unavailable / 13.65% |
LoseJBIO / S&P JBIO unavailable / 8.12% |
LoseJBIO / S&P JBIO unavailable / 14.29% |
| 2018-Q40/3 |
LoseJBIO / S&P JBIO unavailable / -13.52% |
LoseJBIO / S&P JBIO unavailable / 9.05% |
LoseJBIO / S&P JBIO unavailable / 18.23% |
| 2018-Q30/3 |
LoseJBIO / S&P JBIO unavailable / 7.71% |
LoseJBIO / S&P JBIO unavailable / 10.21% |
LoseJBIO / S&P JBIO unavailable / 19.06% |
| 2018-Q20/3 |
LoseJBIO / S&P JBIO unavailable / 3.43% |
LoseJBIO / S&P JBIO unavailable / 9.03% |
LoseJBIO / S&P JBIO unavailable / 14.46% |
| 2018-Q10/3 |
LoseJBIO / S&P JBIO unavailable / -0.76% |
LoseJBIO / S&P JBIO unavailable / 7.68% |
LoseJBIO / S&P JBIO unavailable / 12.46% |
| 2017-Q40/3 |
LoseJBIO / S&P JBIO unavailable / 6.64% |
LoseJBIO / S&P JBIO unavailable / 7.03% |
LoseJBIO / S&P JBIO unavailable / 13.82% |
| 2017-Q30/3 |
LoseJBIO / S&P JBIO unavailable / 4.48% |
LoseJBIO / S&P JBIO unavailable / 5.68% |
LoseJBIO / S&P JBIO unavailable / 17.57% |
| 2017-Q20/3 |
LoseJBIO / S&P JBIO unavailable / 3.09% |
LoseJBIO / S&P JBIO unavailable / 4.83% |
LoseJBIO / S&P JBIO unavailable / 17.74% |
| 2017-Q10/3 |
LoseJBIO / S&P JBIO unavailable / 6.07% |
LoseJBIO / S&P JBIO unavailable / 3.67% |
LoseJBIO / S&P JBIO unavailable / 13.32% |
| 2016-Q40/3 |
LoseJBIO / S&P JBIO unavailable / 3.82% |
LoseJBIO / S&P JBIO unavailable / 2.09% |
LoseJBIO / S&P JBIO unavailable / 7.05% |
| 2016-Q30/3 |
LoseJBIO / S&P JBIO unavailable / 3.85% |
LoseJBIO / S&P JBIO unavailable / 0.20% |
LoseJBIO / S&P JBIO unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | JBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 169.49% | 20.78% |
| Annualized return | 169.49% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | JBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -96.57% | 83.14% |
| Annualized return | -49.05% | 12.86% |
10Y · 2021-06-30 to 2026-08-27
| Metric | JBIO total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -97.27% | 319.30% |
| Annualized return | -30.23% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |